Skip to main content

Table 1 Baseline characteristics of patients (n = 154)

From: Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708)

Characteristics N (%)
Median age, years (range) 54.0 (27.0–79.0)
Median BMI at diagnosis, kg/m2 (range) 22.5 (12.9–31.9)
Median baseline CA-125 level, U/mL (range) 808.0 (9.0–19,800.0)
FIGO stage, n (%)
 III 68 (44.2)
 IV 86 (55.8)
ASA score, n (%)
 1–2 122 (79.2)
 3–4 21 (13.6)
 Unknown 11 (7.2)
Histologic subtype, n (%)
 Mucinous 20 (13.0)
 Endometrioid 31 (20.1)
 Clear cell 28 (18.2)
 LGSC 30 (19.5)
 Carcinosarcoma 12 (7.8)
 Undifferentiated 20 (13.0)
 Mixed 5 (3.3)
 Anaplastic 2 (1.3)
 Transitional 3 (2.0)
 Squamous cell carcinoma 2 (1.3)
 Ewing’s sarcoma 1 (0.6)
Method of diagnosis, n (%)
 Ascites cytology 59 (38.3)
 Pleural effusion cytology 14 (9.1)
 Aspiration biopsy 31 (20.1)
 Diagnostic laparoscopy 24 (15.6)
 Diagnostic laparotomy 4 (2.6)
 Laparoscopy in other hospital 12 (7.8)
 Laparotomy in other hospital 1 (0.6)
 Others 5 (3.3)
 Not diagnosed before NAC 4 (2.6)
Confirm the histologic subtype before NAC, n (%)
 No 108 (70.1)
 Yes 46 (29.9)
  HGSC 5 (3.3)
  Mucinous 7 (4.6)
  Endometrioid 4 (2.6)
  Clear cell 8 (5.2)
  LGSC 9 (5.9)
  Carcinosarcoma 2 (1.3)
  Others 11 (7.1)
Reasons for performing NAC*, n (%)
 Old age / poor ECOG 24 (15.6)
 High tumor burden 106 (68.8)
 Considered as HGSC before NAC 8 (5.2)
 Refer from other hospital after NAC 5 (3.3)
 Others 30 (19.5)
NAC regimens, n (%)
 Paclitaxel + carboplatin 137 (89.0)
 Paclitaxel + cisplatin 6 (3.9)
 Docetaxel + carboplatin 8 (5.2)
 Paclitaxel + carboplatin + bevacizumab 1 (0.6)
 Others 2 (1.3)
POAC regimens, n (%)
 Paclitaxel + carboplatin 114 (74.0)
 Paclitaxel + cisplatin 5 (3.2)
 Docetaxel + carboplatin 9 (5.8)
 Paclitaxel + carboplatin + bevacizumab 1 (0.6)
 Others 17 (11.0)
 Not done 8 (5.2)
  1. BMI body mass index, CA 125 cancer antigen 125, FIGO Federation of Gynecology and Obstetrics, ASA American Society of Anesthesiologists, NAC neoadjuvant chemotherapy, POAC postoperative adjuvant chemotherapy, HGSC high-grade serous carcinoma, LGSC low-grade serous carcinoma, ECOG Eastern Cooperative Oncology Group
  2. *Multi-selectable
\